Small-Cap REIT ETF ...
Health Care: Drugs
Isis Pharmaceuticals (ISIS: NASDAQ)
$20.66 0.50 | 2.48%
05/17/13 - 04:00 PM ET
1.73M / 1.62M
Vol / Avg. Vol:20.30 / 20.16
Open / Prev. Close:20.07 - 20.75
Today's Range:7.56 - 23.03
52 Wk Range:93.10%
Performance YTD:TheStreet Rating:
Portfolios with ISIS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- UserCy Winther
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Setting Up...
- ContributorUnder-$10 Setting Up To Tra...
- UserNext Generation
- Contributor10 Biotech Stocks on Clinic...
Latest ISIS Headlines from TheStreet
- Isis Stock Falls On Unusually High Volume (ISIS) 05.08.13 | 04:05 pm
- Isis Reaches New 52-Week High (ISIS) 05.03.13 | 10:05 am
- Cramer's 'Mad Money' Recap: Good Earnings, Bad Market 05.01.13 | 08:05 pm
- Isis Stock Hits New 52-Week High (ISIS) 04.19.13 | 09:04 am
- Cramer's 'Mad Money' Recap: Risk vs. Reward 04.03.13 | 08:04 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- 4 Stocks Rising on Big Volume 01.31.13 | 08:01 am
- Aegerion CEO Speaks On Juxtapid Launch, Orphan Drug Pricing And Competition 01.30.13 | 06:01 am
- Isis Pharmaceuticals Stock Upgraded (ISIS) 01.28.13 | 04:01 am
- 'Mad Money' Lightning Round: I'd Buy Duke Energy 01.24.13 | 06:01 am
Press Releases for ISIS
- Isis Pharmaceuticals To Present At The 2013 UBS Global Healthcare Conference - PR Newswire 05.13.13 | 07:05 am
- Isis Pharmaceuticals Earns $3.5 Million From Biogen Idec - PR Newswire 05.09.13 | 04:05 pm
- Isis Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference - PR Newswire 05.09.13 | 02:05 pm
- Isis Pharmaceuticals Prices Public Offering Of Common Stock - PR Newswire 05.08.13 | 09:05 pm
- Isis Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 05.07.13 | 04:05 pm
- Isis Pharmaceuticals Announces The Initiation Of A Clinical Study Of ISIS-STAT3 Rx In Patients With Liver Cancer - PR Newswire 05.06.13 | 07:05 am
- ISIS Pharmaceuticals Initiates A Clinical Study Of ISIS-SMN Rx In Infants With Spinal Muscular Atrophy - PR Newswire 04.23.13 | 07:04 am
- Isis Pharmaceuticals To Present At The 12th Annual Needham Healthcare Conference - PR Newswire 04.22.13 | 05:04 pm
- Roche And Isis Pharmaceuticals Form Alliance For Huntington's Disease - PR Newswire 04.08.13 | 09:04 am
- Isis Initiates Phase 1 Study Of ISIS-APOA Rx To Treat Atherosclerosis - PR Newswire 04.03.13 | 07:04 am
Partner Headlines for ISIS
- Isis Pharmaceuticals Inc (ISIS): Today's Most Compelling Stock Buy - NASDAQ 05.17.13 | 05:05 pm
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Isis Pharma Issues Update on CHMP Opinion on KYNAMRO - Benzinga 03.22.13 | 02:03 pm
- Revenues Decline at Alnylam - Analyst Blog - Zacks 11.07.12 | 09:11 am
- Isis Pharmaceuticals To Receive $1.1 Million From Alnylam - Benzinga 10.23.12 | 01:10 pm
- Benzinga Mid-Day Market Update - Benzinga 10.17.12 | 12:10 pm
- UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing - Benzinga 10.16.12 | 01:10 pm
- Alnylam-ISIS Venture Prices IPO - Analyst Blog - Zacks 10.05.12 | 06:10 pm
- Alnylam/Isis's Regulus to Go Public - Analyst Blog - Zacks 08.22.12 | 07:08 pm
- Biogen Inks Deal with Regulus - Analyst Blog - Zacks 08.16.12 | 06:08 pm
